Many people with stage II or III colon cancer receive additional, or adjuvant, chemotherapy following surgery. However, clinical trials have shown that this treatment doesn’t improve the chances of survival for every patient. A study
in Health
Study identifies biomarker that could predict whether colon cancer patients benefit from chemotherapy
